Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were ...

Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo ...

Objectives To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological ...

Upadacitinib was associated with the highest crude prevalence of acne (15.9%), followed by tofacitinib (4.3%) and filgotinib (1.9%). A dose-response relationship was identified for upadacitinib and ...

Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S ...

Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S ...

BARCELONA, Spain — The JAK inhibitor upadacitinib can effectively treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to results from a new clinical trial ...

By week 12, 41.9% of participants with baseline total spinal pain scores of at least 4 achieved the primary endpoint. Mean total back pain scores decreased from 6.9 (n=621) at baseline to 4.4 (n=433) ...

DHS clarifies the intended message in sharing the poster on social media: “Help your country locate and arrest illegal aliens. To report criminal activity, call 866-DHS-2-ICE (866-347-2423).: ...

Park Bo Gum, Kim So Hyun, Lee Sang Yi, And More Strike Powerful Poses With Their Signature Gear In “Good Boy” Poster. Drama Preview. Jun 10, 2025 . by M Lim.

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

In April 2025, the US Food and Drug Administration (FDA) approved Rinvoq ® (upadacitinib; AbbVie, Inc) for the treatment of adults with giant cell arteritis (GCA).. Upadacitinib is a Janus kinase (JAK ...